{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"34"}],"units":"Participants"}],"description":"Count of participants with successful mobilization and collection of PBSCs. Defined as collection of \\> 2 x 10\\^6 CD34/kg. The current study will be deemed to be potentially efficacious if the observed rate of success is at least 80%.","groups":[{"description":"Patients receive bendamustine hydrochloride IV over 30-60 minutes on days 1 and 2, etoposide IV over 60-240 minutes on days 1-3, dexamethasone PO on days 1-4, and filgrastim SC beginning on day 5 and continuing until peripheral blood stem cell collection is complete. Patients undergo leukapheresis daily for a minimum of 3 days or until \\> 5 x 10\\^6 CD34+/kg has been collected.\n\n.\n\nbendamustine hydrochloride: Given IV\n\ndexamethasone: Given PO\n\nfilgrastim: Given SC\n\nleukapheresis: Given IV\n\nlaboratory biomarker analysis: Correlative studies\n\nflow cytometry: Correlative studies\n\netoposide: Given IV","id":"OG000","title":"Treatment (Chemotherapy and Colony-stimulating Factor)"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Within 7 days of apheresis and within 6 weeks of receiving bendamustine hydrochloride","title":"Successful Mobilization and Collection of PBSCs","type":"PRIMARY","unitOfMeasure":"Participants"}